Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRC NYSE:GKOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRCAtriCure$28.79$28.08$25.36▼$43.18$1.46B1.26739,788 shs700,874 shsGKOSGlaukos$126.760.0%$124.00$73.16▼$148.11$7.44B0.831.30 million shs707,972 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRCAtriCure0.00%+6.24%+2.38%-5.42%-8.95%GKOSGlaukos0.00%+1.57%-11.68%+28.12%+29.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRCAtriCure$28.79$28.08$25.36▼$43.18$1.46B1.26739,788 shs700,874 shsGKOSGlaukos$126.760.0%$124.00$73.16▼$148.11$7.44B0.831.30 million shs707,972 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRCAtriCure0.00%+6.24%+2.38%-5.42%-8.95%GKOSGlaukos0.00%+1.57%-11.68%+28.12%+29.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRCAtriCure 2.64Moderate Buy$48.7169.21% UpsideGKOSGlaukos 2.79Moderate Buy$148.0016.76% UpsideCurrent Analyst Ratings BreakdownLatest ATRC and GKOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GKOSGlaukos CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $162.006/10/2026GKOSGlaukos BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$162.006/4/2026ATRCAtriCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/26/2026GKOSGlaukos William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/21/2026GKOSGlaukos BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$141.00 ➝ $162.005/6/2026ATRCAtriCure Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $55.005/6/2026ATRCAtriCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026ATRCAtriCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/30/2026GKOSGlaukos Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$170.004/30/2026GKOSGlaukos CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$135.00 ➝ $140.004/30/2026GKOSGlaukos JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$120.00 ➝ $140.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRCAtriCure$534.53M2.73$0.31 per share91.98$9.89 per share2.91GKOSGlaukos$507.44M14.67N/AN/A$11.42 per share11.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRCAtriCure-$11.45M-$0.10N/A77.81N/A-0.83%0.29%0.22%8/4/2026 (Estimated)GKOSGlaukos-$187.69M-$3.28N/A269.70N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)Latest ATRC and GKOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026GKOSGlaukos-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRCAtriCureN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRCAtriCure0.154.293.18GKOSGlaukos0.105.434.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRCAtriCure99.11%GKOSGlaukos99.04%Insider OwnershipCompanyInsider OwnershipATRCAtriCure4.00%GKOSGlaukos5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRCAtriCure1,30050.64 million48.62 millionOptionableGKOSGlaukos1,09458.73 million55.27 millionOptionableATRC and GKOS HeadlinesRecent News About These CompaniesLandscape Capital Management L.L.C. Boosts Stake in Glaukos Corporation $GKOS1 hour ago | marketbeat.comGlaukos Corporation $GKOS Stock Holdings Reduced by Rhenman & Partners Asset Management ABJune 13 at 5:48 AM | marketbeat.comGlaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street ZenJune 13 at 1:26 AM | marketbeat.comClearbridge Investments LLC Lowers Stake in Glaukos Corporation $GKOSJune 11, 2026 | marketbeat.comWhy Is NYSE Composite Watching Glaukos’ iDose TR Adoption Momentum?June 10, 2026 | kalkinemedia.comKGlaukos (NYSE:GKOS) Stock Price Down 4.5% - Here's WhyJune 10, 2026 | marketbeat.comGlaukos (NYSE:GKOS) Given "Buy" Rating at BTIG ResearchJune 10, 2026 | marketbeat.comCenterBook Partners LP Makes New Investment in Glaukos Corporation $GKOSJune 10, 2026 | marketbeat.comA Look At Glaukos (GKOS) Valuation After Recent Share Price SwingsJune 9, 2026 | finance.yahoo.comAnalysts Conflicted on These Healthcare Names: Moderna (MRNA) and Glaukos (GKOS)June 8, 2026 | theglobeandmail.comGoldman Sachs Group Inc. Acquires 913,458 Shares of Glaukos Corporation $GKOSJune 8, 2026 | marketbeat.comNorges Bank Purchases New Stake in Glaukos Corporation $GKOSJune 8, 2026 | marketbeat.comHavemeyer Place LP Makes New $1.53 Million Investment in Glaukos Corporation $GKOSJune 7, 2026 | marketbeat.comHere's Why You Should Retain Glaukos Stock in Your Portfolio NowJune 5, 2026 | zacks.comGlaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 3, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Glaukos (GKOS)May 30, 2026 | theglobeandmail.comGlaukos (NYSE:GKOS) Downgraded to Hold Rating by Wall Street ZenMay 30, 2026 | marketbeat.comWilliam Blair Investment Management LLC Has $124.98 Million Stake in Glaukos Corporation $GKOSMay 24, 2026 | marketbeat.comLisanti Capital Growth LLC Acquires New Position in Glaukos Corporation $GKOSMay 24, 2026 | marketbeat.comGlaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressureMay 22, 2026 | quiverquant.comQGlaukos (NYSE:GKOS) Shares Down 7.4% - Here's What HappenedMay 22, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRC and GKOS Company DescriptionsAtriCure NASDAQ:ATRC$28.79 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$28.81 +0.02 (+0.07%) As of 06/12/2026 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Glaukos NYSE:GKOS$126.76 -0.05 (-0.04%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$126.86 +0.10 (+0.08%) As of 06/12/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
